Illumina CEO Jay Flatley tells Xconomy's Luke Timmerman that for a long time there was no innovation in the industry until the advent of next-gen sequencing which caused "huge amount of money" to be invested in the space. Currently, Flatley considers Life Technologies to be Illumina's primary competitor, but says his company is "way ahead" in terms of market share.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.